<?xml version="1.0" encoding="iso-8859-1" ?>
<PASBIO>
    <framesest>
        <predicate lemma="decrease">
            <roleset id="decrease.01" name="make smaller&#x0A;" wordnet="2">
                <roles>
                    <role n="0" descr="agent&#x0A;" />
                    <role n="1" descr="thing decreased&#x0A;" />
                    <role n="2" descr="location&#x0A;" />
                </roles>
                <example src="EGRAM" no="0">
                    <text>Deletion of the arcA gene caused about a 2-fold increase in the ptsG expression, and glucose consumption were significantly decreased by overexpression of ArcA will significantly.</text>
                    <arg n="0">overexpression of ArcA</arg>
                    <arg n="1">glucose consumption</arg>
                </example>
                <example src="EGRAM" no="1">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and overexpression of ArcA is believed to significantly decrease glucose consumption.</text>
                    <arg n="0">overexpression of ArcA</arg>
                    <arg n="1">glucose consumption</arg>
                </example>
                <example src="EGRAM" no="2">
                    <text>Deletion of the arcA gene has caused about a 2-fold increase in the ptsG expression, and overexpression of ArcA will have significantly decreased glucose consumption.</text>
                    <arg n="0">overexpression of ArcA</arg>
                    <arg n="1">glucose consumption</arg>
                </example>
                <example src="EGRAM" no="3">
                    <text>If this distance of 30 amino acids is not maintained, as in human AspRS chimera#1, or in yeast LysTS chimera#1 and yeast AsnRS chimera#2 (Figure 5B), the binding to tRNA is strongly affected and the protection was shown to be decreased, or even abolished in the case of human AspRS chimera#1 (Table).</text>
                    <arg n="1">the protection</arg>
                </example>
                <example src="EGRAM" no="4">
                    <text>In brain areas of schizophrenia patients homologous to those of the nonpsychiatric subjects, the RELN mRNA content might be significantly decreased (4050%; see Table 2).</text>
                    <arg n="0">the RELN mRNA content</arg>
                </example>
                <example src="EGRAM" no="5">
                    <text>In contrast, only low levels of the truncated RAP1 peptides are detected (consistent with that expression levels is lowered and methionine content is decreased), and neither RAP2 nor RAP3 is co-immunoprecipitated in the RAP1 mutants.</text>
                    <arg n="1">methionine content</arg>
                </example>
                <example src="EGRAM" no="6">
                    <text>In contrast, only low levels of the truncated RAP1 peptides are detected (consistent with that expression levels may be lowered and methionine content may be decreased), and neither RAP2 nor RAP3 is co-immunoprecipitated in the RAP1 mutants.</text>
                    <arg n="1">methionine content</arg>
                </example>
                <example src="EGRAM" no="7">
                    <text>In contrast, only low levels of the truncated RAP1 peptides are detected (consistent with that expression levels may have been lowered and methionine content may have been decreased), and neither RAP2 nor RAP3 is co-immunoprecipitated in the RAP1 mutants.</text>
                    <arg n="1">methionine content</arg>
                </example>
                <example src="EGRAM" no="8">
                    <text>In contrast, only low levels of the truncated RAP1 peptides are detected (consistent with that expression levels may have been lowered and methionine content may have been decreased), and neither RAP2 nor RAP3 is co-immunoprecipitated in the RAP1 mutants.</text>
                    <arg n="1">methionine content</arg>
                </example>
                <example src="EGRAM" no="9">
                    <text>MEF2-binding sites have been reported in several cardiac promoters and promoter activity was able to be decreased by their mutation in cardiomyocytes.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                    <arg n="2">cardiomyocytes</arg>
                </example>
                <example src="EGRAM" no="10">
                    <text>MEF2-binding sites have been reported in several cardiac promoters and their mutation can decrease promoter activity in cardiomyocytes.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                    <arg n="2">cardiomyocytes</arg>
                </example>
                <example src="EGRAM" no="11">
                    <text>Nitrite induction of the nirB promoter will be decreased by disruption of narL which is not suppressing induction by nitrate, suggesting that there may be a second nitrate-responsive factor.</text>
                    <arg n="0">Disruption of narL</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="EGRAM" no="12">
                    <text>The levels of Clara cell secretory protein can have been decreased in NLF from smokers, and it has also been found that NLF from smokers contained increased proportions of a truncated variant of lipocortin-1, threee acidic forms of alpha (1)-antitrypsin, and one phosphorylated form of cystatin S.Syntrophin binds to an alternatively spliced exon of dystrophin.</text>
                    <arg n="1">levels of Clara cell secretory protein</arg>
                </example>
                <example src="EGRAM" no="13">
                    <text>The levels of Clara cell secretory protein is able to be decreased in NLF from smokers, and it has also been found that NLF from smokers contained increased proportions of a truncated variant of lipocortin-1, threee acidic forms of alpha (1)-antitrypsin, and one phosphorylated form of cystatin S.Syntrophin binds to an alternatively spliced exon of dystrophin.</text>
                    <arg n="1">levels of Clara cell secretory protein</arg>
                </example>
                <example src="EGRAM" no="14">
                    <text>The levels of Clara cell secretory protein is able to be decreased in NLF from smokers, and it is also found that NLF from smokers contained increased proportions of a truncated variant of lipocortin-1, threee acidic forms of alpha (1)-antitrypsin, and one phosphorylated form of cystatin S.Syntrophin binds to an alternatively spliced exon of dystrophin.</text>
                    <arg n="1">levels of Clara cell secretory protein</arg>
                </example>
                <example src="EGRAM" no="15">
                    <text>The levels of Clara cell secretory protein is decreased in NLF from smokers, and it is also found that NLF from smokers contained increased proportions of a truncated variant of lipocortin-1, threee acidic forms of alpha (1)-antitrypsin, and one phosphorylated form of cystatin S.Syntrophin binds to an alternatively spliced exon of dystrophin.</text>
                    <arg n="1">levels of Clara cell secretory protein</arg>
                </example>
                <example src="EGRAM" no="16">
                    <text>The levels of Clara cell secretory protein is shown to be decreased in NLF from smokers, and it is also found that NLF from smokers contained increased proportions of a truncated variant of lipocortin-1, threee acidic forms of alpha (1)-antitrypsin, and one phosphorylated form of cystatin S.Syntrophin binds to an alternatively spliced exon of dystrophin.</text>
                    <arg n="1">levels of Clara cell secretory protein</arg>
                </example>
                <example src="EGRAM" no="17">
                    <text>The levels of Clara cell secretory protein was believed to be decreased in NLF from smokers, and it has also been found that NLF from smokers contained increased proportions of a truncated variant of lipocortin-1, threee acidic forms of alpha (1)-antitrypsin, and one phosphorylated form of cystatin S.Syntrophin binds to an alternatively spliced exon of dystrophin.</text>
                    <arg n="1">levels of Clara cell secretory protein</arg>
                </example>
                <example src="EGRAM" no="18">
                    <text>The production of C51 microcin had the ability to to decrease or be absent in rpoS, crp and cya mutant cells.</text>
                    <arg n="1">The production of C51 microcin</arg>
                    <arg n="2">rpoS, crp and cya mutant cells</arg>
                </example>
                <example src="EGRAM" no="19">
                    <text>The production of C51 microcin is able to decrease or be absent in rpoS, crp and cya mutant cells.</text>
                    <arg n="1">The production of C51 microcin</arg>
                    <arg n="2">rpoS, crp and cya mutant cells</arg>
                </example>
                <example src="EGRAM" no="20">
                    <text>Treatment with melatonin is able to decrease lipid peroxide synthesis, and permits a recovery of both reduced glutathione and scavenger enzyme activity.</text>
                    <arg n="0">Treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="EGRAM" no="21">
                    <text>Treatment with melatonin is able to decrease lipid peroxide synthesis, and permits a recovery of both reduced glutathione and scavenger enzyme activity.</text>
                    <arg n="0">Treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="EGRAM" no="22">
                    <text>expression of OmpF porin in multiple-antibiotic-resistant (Mar) mutants of Escherichia coli has been decreased by marA locus.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                    <arg n="2">multiple-antibiotic-resistant (Mar) mutants of Escherichia coli</arg>
                </example>
                <example src="EGRAM" no="23">
                    <text>expression of OmpF porin in multiple-antibiotic-resistant (Mar) mutants of Escherichia coli was believed to be decreased by marA locus.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                    <arg n="2">multiple-antibiotic-resistant (Mar) mutants of Escherichia coli</arg>
                </example>
                <example src="EGRAM" no="24">
                    <text>expression of OmpF porin in multiple-antibiotic-resistant (Mar) mutants of Escherichia coli was decreased by marA locus.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                    <arg n="2">multiple-antibiotic-resistant (Mar) mutants of Escherichia coli</arg>
                </example>
                <example src="EGRAM" no="25">
                    <text>marA locus is able to decrease expression of OmpF porin in multiple-antibiotic-resistant (Mar) mutants of Escherichia coli.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                    <arg n="2">multiple-antibiotic-resistant (Mar) mutants of Escherichia coli</arg>
                </example>
                <example src="EMBO" no="1">
                    <text>In contrast, only low levels of the truncated RAP1 peptides were detected (consistent with lower expression levels and decreased methionine content), and neither RAP2 nor RAP3 was co-immunoprecipitated in the RAP1 mutants.</text>
                    <arg n="1">methionine content</arg>
                </example>
                <example src="PERMUTATE" no="1">
                    <text>Deletion of the arcA gene caused about a 2-fold increase in the ptsG expression, and marA locus was observed to have significantly decreased expression of OmpF porin.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                </example>
                <example src="PERMUTATE" no="2">
                    <text>Deletion of the arcA gene caused about a 2-fold increase in the ptsG expression, and promoter activity have been significantly decreased by their mutation will significantly.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="3">
                    <text>Deletion of the arcA gene caused about a 2-fold increase in the ptsG expression, and their mutation significantly decreased promoter activity.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="4">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and Treatment with melatonin is shown to have significantly decreased lipid peroxide synthesis.</text>
                    <arg n="0">Treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="PERMUTATE" no="5">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and Treatment with melatonin may have significantly decreased lipid peroxide synthesis.</text>
                    <arg n="0">Treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="PERMUTATE" no="6">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and expression of OmpF porin are significantly decreased by marA locus will significantly.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                </example>
                <example src="PERMUTATE" no="7">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and lipid peroxide synthesis can have been significantly decreased by Treatment with melatonin will significantly.</text>
                    <arg n="0">Treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="PERMUTATE" no="8">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and lipid peroxide synthesis is able to be significantly decreased by Treatment with melatonin will significantly.</text>
                    <arg n="0">Treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="PERMUTATE" no="9">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and lipid peroxide synthesis will have been significantly decreased by Treatment with melatonin will significantly.</text>
                    <arg n="0">Treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="PERMUTATE" no="10">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and marA locus is observed to significantly decrease expression of OmpF porin.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                </example>
                <example src="PERMUTATE" no="11">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and marA locus may have significantly decreased expression of OmpF porin.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                </example>
                <example src="PERMUTATE" no="12">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and nitrite induction of the nirB promoter will have been significantly decreased by Disruption of narL will significantly.</text>
                    <arg n="0">Disruption of narL</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="PERMUTATE" no="13">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and nitrite induction of the nirB promoter would be significantly decreased by Disruption of narL will significantly.</text>
                    <arg n="0">Disruption of narL</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="PERMUTATE" no="14">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and promoter activity are significantly decreased by their mutation will significantly.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="15">
                    <text>Deletion of the arcA gene causes about a 2-fold increase in the ptsG expression, and promoter activity was shown to be significantly decreased by their mutation will significantly.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="16">
                    <text>Deletion of the arcA gene has caused about a 2-fold increase in the ptsG expression, and Treatment with melatonin will have significantly decreased lipid peroxide synthesis.</text>
                    <arg n="0">Treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="PERMUTATE" no="17">
                    <text>Disruption of narL was able to decrease nitrite induction of the nirB promoter, and permitted a recovery of both reduced glutathione and scavenger enzyme activity.</text>
                    <arg n="0">Disruption of narL</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="PERMUTATE" no="18">
                    <text>Disruption of narL will decrease nitrite induction of the nirB promoter, and permits a recovery of both reduced glutathione and scavenger enzyme activity.</text>
                    <arg n="0">Disruption of narL</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="PERMUTATE" no="19">
                    <text>Disruption of narL would decrease nitrite induction of the nirB promoter, and permitted a recovery of both reduced glutathione and scavenger enzyme activity.</text>
                    <arg n="0">Disruption of narL</arg>
                    <arg n="1">nitrite induction of the nirB promoter</arg>
                </example>
                <example src="PERMUTATE" no="20">
                    <text>In brain areas of schizophrenia patients homologous to those of the nonpsychiatric subjects, Disruption of narL could be significantly decreased (4050%; see Table 2).</text>
                    <arg n="0">Disruption of narL</arg>
                </example>
                <example src="PERMUTATE" no="21">
                    <text>In brain areas of schizophrenia patients homologous to those of the nonpsychiatric subjects, Disruption of narL has been significantly decreased (4050%; see Table 2).</text>
                    <arg n="0">Disruption of narL</arg>
                </example>
                <example src="PERMUTATE" no="22">
                    <text>In brain areas of schizophrenia patients homologous to those of the nonpsychiatric subjects, Disruption of narL is able to be significantly decreased (4050%; see Table 2).</text>
                    <arg n="0">Disruption of narL</arg>
                </example>
                <example src="PERMUTATE" no="23">
                    <text>In brain areas of schizophrenia patients homologous to those of the nonpsychiatric subjects, Disruption of narL is being significantly decreasing (4050%; see Table 2).</text>
                    <arg n="0">Disruption of narL</arg>
                </example>
                <example src="PERMUTATE" no="24">
                    <text>In brain areas of schizophrenia patients homologous to those of the nonpsychiatric subjects, Disruption of narL is believed to be significantly decreased (4050%; see Table 2).</text>
                    <arg n="0">Disruption of narL</arg>
                </example>
                <example src="PERMUTATE" no="25">
                    <text>In brain areas of schizophrenia patients homologous to those of the nonpsychiatric subjects, Disruption of narL may be significantly decreased (4050%; see Table 2).</text>
                    <arg n="0">Disruption of narL</arg>
                </example>
                <example src="PERMUTATE" no="26">
                    <text>In brain areas of schizophrenia patients homologous to those of the nonpsychiatric subjects, Disruption of narL was able to be significantly decreased (4050%; see Table 2).</text>
                    <arg n="0">Disruption of narL</arg>
                </example>
                <example src="PERMUTATE" no="27">
                    <text>In brain areas of schizophrenia patients homologous to those of the nonpsychiatric subjects, Disruption of narL was shown to be significantly decreased (4050%; see Table 2).</text>
                    <arg n="0">Disruption of narL</arg>
                </example>
                <example src="PERMUTATE" no="28">
                    <text>In brain areas of schizophrenia patients homologous to those of the nonpsychiatric subjects, Treatment with melatonin is believed to be significantly decreased (4050%; see Table 2).</text>
                    <arg n="0">Treatment with melatonin</arg>
                </example>
                <example src="PERMUTATE" no="29">
                    <text>In brain areas of schizophrenia patients homologous to those of the nonpsychiatric subjects, Treatment with melatonin is shown to be significantly decreased (4050%; see Table 2).</text>
                    <arg n="0">Treatment with melatonin</arg>
                </example>
                <example src="PERMUTATE" no="30">
                    <text>In brain areas of schizophrenia patients homologous to those of the nonpsychiatric subjects, Treatment with melatonin is significantly decreased (4050%; see Table 2).</text>
                    <arg n="0">Treatment with melatonin</arg>
                </example>
                <example src="PERMUTATE" no="31">
                    <text>In brain areas of schizophrenia patients homologous to those of the nonpsychiatric subjects, Treatment with melatonin will have been significantly decreased (4050%; see Table 2).</text>
                    <arg n="0">Treatment with melatonin</arg>
                </example>
                <example src="PERMUTATE" no="32">
                    <text>In brain areas of schizophrenia patients homologous to those of the nonpsychiatric subjects, overexpression of ArcA can have been significantly decreased (4050%; see Table 2).</text>
                    <arg n="0">overexpression of ArcA</arg>
                </example>
                <example src="PERMUTATE" no="33">
                    <text>In brain areas of schizophrenia patients homologous to those of the nonpsychiatric subjects, overexpression of ArcA could be significantly decreased (4050%; see Table 2).</text>
                    <arg n="0">overexpression of ArcA</arg>
                </example>
                <example src="PERMUTATE" no="34">
                    <text>In brain areas of schizophrenia patients homologous to those of the nonpsychiatric subjects, overexpression of ArcA is able to be significantly decreased (4050%; see Table 2).</text>
                    <arg n="0">overexpression of ArcA</arg>
                </example>
                <example src="PERMUTATE" no="35">
                    <text>In brain areas of schizophrenia patients homologous to those of the nonpsychiatric subjects, overexpression of ArcA would be significantly decreased (4050%; see Table 2).</text>
                    <arg n="0">overexpression of ArcA</arg>
                </example>
                <example src="PERMUTATE" no="36">
                    <text>In contrast, only low levels of the truncated RAP1 peptides will be detected (consistent with that expression levels will be lowered and The production of C51 microcin will be decreased), and neither RAP2 nor RAP3 will be co-immunoprecipitated in the RAP1 mutants.</text>
                    <arg n="1">The production of C51 microcin</arg>
                </example>
                <example src="PERMUTATE" no="37">
                    <text>In contrast, only low levels of the truncated RAP1 peptides will be detected (consistent with that expression levels will have been lowered and The production of C51 microcin will have been decreased), and neither RAP2 nor RAP3 will be co-immunoprecipitated in the RAP1 mutants.</text>
                    <arg n="1">The production of C51 microcin</arg>
                </example>
                <example src="PERMUTATE" no="38">
                    <text>In contrast, only low levels of the truncated RAP1 peptides will be detected (consistent with that expression levels will have been lowered and the RELN mRNA content will have been decreased), and neither RAP2 nor RAP3 will be co-immunoprecipitated in the RAP1 mutants.</text>
                    <arg n="1">the RELN mRNA content</arg>
                </example>
                <example src="PERMUTATE" no="39">
                    <text>MEF2-binding sites have been reported in several cardiac promoters and expression of OmpF porin can be decreased by marA locus in multiple-antibiotic-resistant (Mar) mutants of Escherichia coli.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                    <arg n="2">multiple-antibiotic-resistant (Mar) mutants of Escherichia coli</arg>
                </example>
                <example src="PERMUTATE" no="40">
                    <text>MEF2-binding sites have been reported in several cardiac promoters and expression of OmpF porin would be decreased by marA locus in multiple-antibiotic-resistant (Mar) mutants of Escherichia coli.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                    <arg n="2">multiple-antibiotic-resistant (Mar) mutants of Escherichia coli</arg>
                </example>
                <example src="PERMUTATE" no="41">
                    <text>Treatment with melatonin decreased lipid peroxide synthesis whilst not suppressing induction by nitrate, suggesting that there may be a second nitrate-responsive factor.</text>
                    <arg n="0">Treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="PERMUTATE" no="42">
                    <text>Treatment with melatonin is shown to decrease lipid peroxide synthesis whilst not suppressing induction by nitrate, suggesting that there may be a second nitrate-responsive factor.</text>
                    <arg n="0">Treatment with melatonin</arg>
                    <arg n="1">lipid peroxide synthesis</arg>
                </example>
                <example src="PERMUTATE" no="43">
                    <text>marA locus has decreased expression of OmpF porin, and permitted a recovery of both reduced glutathione and scavenger enzyme activity.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                </example>
                <example src="PERMUTATE" no="44">
                    <text>marA locus is shown to decrease expression of OmpF porin whilst not suppressing induction by nitrate, suggesting that there may be a second nitrate-responsive factor.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                </example>
                <example src="PERMUTATE" no="45">
                    <text>marA locus is shown to decrease expression of OmpF porin, and permits a recovery of both reduced glutathione and scavenger enzyme activity.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                </example>
                <example src="PERMUTATE" no="46">
                    <text>marA locus may decrease expression of OmpF porin, and permits a recovery of both reduced glutathione and scavenger enzyme activity.</text>
                    <arg n="0">marA locus</arg>
                    <arg n="1">expression of OmpF porin</arg>
                </example>
                <example src="PERMUTATE" no="47">
                    <text>overexpression of ArcA has decreased glucose consumption whilst not suppressing induction by nitrate, suggesting that there might be a second nitrate-responsive factor.</text>
                    <arg n="0">overexpression of ArcA</arg>
                    <arg n="1">glucose consumption</arg>
                </example>
                <example src="PERMUTATE" no="48">
                    <text>overexpression of ArcA will decrease glucose consumption, and permits a recovery of both reduced glutathione and scavenger enzyme activity.</text>
                    <arg n="0">overexpression of ArcA</arg>
                    <arg n="1">glucose consumption</arg>
                </example>
                <example src="PERMUTATE" no="49">
                    <text>their mutation was able to decrease promoter activity in cardiomyocytes.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                    <arg n="2">cardiomyocytes</arg>
                </example>
                <example src="PERMUTATE" no="50">
                    <text>their mutation will decrease promoter activity in cardiomyocytes.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                    <arg n="2">cardiomyocytes</arg>
                </example>
                <example src="PERMUTATE" no="51">
                    <text>their mutation will have decreased promoter activity whilst not suppressing induction by nitrate, suggesting that there may be a second nitrate-responsive factor.</text>
                    <arg n="0">their mutation</arg>
                    <arg n="1">promoter activity</arg>
                </example>
                <example src="REPLACE" no="1">
                    <text>In contrast, only low levels of the truncated RAP1 peptides were detected (consistent with that expression levels was able to be lowered and levels of Clara cell secretory protein was able to be decreased), and neither RAP2 nor RAP3 was be co-immunoprecipitated in the RAP1 mutants.</text>
                    <arg n="1">levels of Clara cell secretory protein</arg>
                </example>
                <example src="REPLACE" no="2">
                    <text>In contrast, only low levels of the truncated RAP1 peptides will be detected (consistent with that expression levels will have been lowered and the protection will have been decreased), and neither RAP2 nor RAP3 will be co-immunoprecipitated in the RAP1 mutants.</text>
                    <arg n="1">the protection</arg>
                </example>
            </roleset>
        </predicate>
    </framesest>
</PASBIO>
